| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
717 |
621 |
$81K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
865 |
725 |
$65K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,121 |
914 |
$41K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
498 |
412 |
$37K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
964 |
581 |
$29K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
422 |
252 |
$28K |
| 96127 |
|
1,571 |
1,298 |
$23K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
413 |
346 |
$23K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
617 |
493 |
$14K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,364 |
1,024 |
$11K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
188 |
154 |
$10K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
249 |
212 |
$6K |
| 99215 |
Prolong outpt/office vis |
74 |
64 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
71 |
61 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
338 |
153 |
$926.80 |
| 87634 |
|
14 |
12 |
$842.40 |
| 99000 |
|
1,714 |
633 |
$414.03 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
13 |
12 |
$0.48 |